Race Oncology completes board renewal to drive next phase of growth

Race Oncology Ltd (ASX: RAC, OTC: RAONF) executive chair Dr Peter Smith joins Proactive’s Tylah Tully to discuss the latest updates at the company. It has completed a board renewal process, marking a significant milestone as the company prepares for its next phase of development. The company expressed gratitude to non-executive chair Mary Harney and non-executive director and former CEO/MD Phil Lynch for their four years of service. As part of the renewal, Dr Smith has been appointed as the executive chair, while Dr Daniel Tillett, the current CEO, will also take on the role of managing director. Additionally, Dr Serge Scrofani has joined the board as an independent non-executive director, bringing more than 28 years of experience in the healthcare sector, including key strategic roles at CSL. Dr Scrofani’s extensive experience in research, strategy and corporate development, particularly in driving strategic initiatives and executing major mergers and acquisitions, is expected to play a pivotal role in Race Oncology’s future. Currently, Dr Scrofani is the principal of Poplar Advisory and he serves on the boards of the Burnet Institute and The Centre for Eye Research. He also holds a PhD in Structural Biology and an MBA from Melbourne Business School. #Proactiveinvestors #RaceOncology #ASX #BoardRenewal, #HealthcareLeadership, #Bisantrene, #CancerTherapies, #ASXNews, #CorporateDevelopment, #StrategicLeadership, #Pharmaceuticals, #HealthcareSector, #BiotechNews, #ExecutiveAppointments, #MedicalResearch, #CorporateStrategy, #HealthcareInnovation #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews